Author

P. G. Rose

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

O. Reizes· 3 shared C. Braley· 2 shared C. Saygin· 2 shared E. Esakov· 2 shared G. Dey· 2 shared J. Lathia· 2 shared R. Debernardo· 2 shared A. B. Nagaraj· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

O. Reizes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 3, 2021

LCK Regulates Homologous Recombination DNA Repair Identifying a New Therapeutic Target for Sensitizing PARP Inhibitors in HR Proficient Ovarian Cancer

G. Dey, R. Bharti, C. Braley…·O. Reizes

This study identifies LCK's role in HR repair in ovarian cancer, showing its inhibition sensitizes HR-proficient tumors to PARP inhibitors.

DOI 10.1101/2021.03.03.433791

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivJun 18, 2020

Pretreatment with LCK Inhibitors Chemosensitizes Cisplatin-Resistant Endometrioid Ovarian Tumors

K. K. Crean-Tate, C. Braley, G. Dey…·O. Reizes

This study shows that pretreatment with LCK inhibitors makes cisplatin-resistant endometrioid ovarian tumors more sensitive to cisplatin, improving cell viability and tumor growth inhibition.

DOI 10.1186/s13048-021-00797-x

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivJun 27, 2017

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors

C. Saygin, A. Wiechert, V. S. Rao…·O. Reizes

This study identifies CD55 as a signaling hub that regulates self-renewal and cisplatin resistance in endometrioid tumors through distinct signaling pathways.

DOI 10.1084/jem.20170438

humanproteomics

𝕏 PostBluesky